BSX vs RMD stock comparison
Boston Scientific vs. Resmed · data as of November 13, 2026
Boston Scientific (BSX) has a market value of about $64.3B, Resmed (RMD) about $33.7B. Over their latest twelve months Boston Scientific had revenue of $21.1B and Resmed $5.7B.
On our five checks Resmed scores higher: 4.2 out of 5 (excellent) against 3.0 (average).
By area, the stronger company is Boston Scientific on future growth; Resmed on track record; Resmed on financial health; Resmed on shareholder returns.
Boston Scientific is cheaper on earnings (P/E 18.8 vs. 21.8).
Boston Scientific leads on 12 of the compared lines and Resmed on 10.
Side by side
| BSX | RMD | |
|---|---|---|
| Size and price | ||
| Market cap | $64.3B | $33.7B |
| Share price | $44.34 | $239.53 |
| Score | ||
| Overall score (of 5) | 3.0 | 4.2 |
| Value | 3 | 3 |
| Future growth | 5 | 4 |
| Track record | 2 | 5 |
| Financial health | 4 | 5 |
| Shareholder returns | 1 | 4 |
| Valuation | ||
| P/E (TTM) | 18.8 | 21.8 |
| Forward P/E | 14.4 | 18.9 |
| Price / free cash flow | 19.3 | 20.9 |
| Price / sales | 3.1 | 5.9 |
| EV / EBITDA | 14.1 | 15.9 |
| PEG | — | 0.83 |
| DCF value vs. price | −58% | −28% |
| Business | ||
| Revenue | $21.1B | $5.7B |
| Net income | $3.5B | $1.6B |
| Free cash flow | $3.3B | $1.6B |
| Net margin | 16.6% | 27.8% |
| Gross margin (5-yr avg.) | 68.9% | 57.9% |
| ROIC (5-yr avg.) | 5.9% | 18.9% |
| Growth | ||
| Revenue growth (1 yr) | 19.9% | 9.8% |
| Revenue growth (5 yrs, per year) | 15.2% | 12.1% |
| EPS growth (5 yrs, per year) | — | 26.3% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$11.3B | $400M |
| Dividend yield | None | 1.10% |
| Shareholder yield | 0.0% | 3.2% |
| Analysts | ||
| Upside to average target | +12% | +10% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: BSX TTM to September 30, 2026, RMD TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Boston Scientific or Resmed?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Resmed scores 4.2 out of 5 and Boston Scientific 3.0; the table shows where each one is stronger.
Is Boston Scientific cheaper than Resmed?
On trailing earnings, Boston Scientific trades at a P/E of 18.8 and Resmed at 21.8, so Boston Scientific is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Boston Scientific or Resmed?
Over five years Boston Scientific grew revenue about 15.2% a year and Resmed about 12.1% a year.
Which pays a higher dividend?
Boston Scientific yields nothing (no dividend) and Resmed 1.10%.
Full Boston Scientific analysis → Full Resmed analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.